Pfizer's Covid pill keeps away severe illness by 89%
Pfizer announced that clinical trials of its experimental Covid-19 pill have been so successful in cutting by 89% the chances of hospitalization or death for adults at risk of developing severe disease, that it's stopping the studies early.
Albert Bourla, Pfizer’s chief executive, called the drug a potential “game-changer” in a statement.
These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of ten hospitalizations.”
The antiviral pill, which is combined with a low dose of an HIV drug called ritonavir, can reduce hospitalizations or deaths from Covid-19 by up to 89 percent among high-risk patients, Pfizer said in a news release.
Pfizer said it planned to ask the Food and Drug Administration to authorize the drug combination “as soon as possible.”
Esta publicación es para usuarios registrados
Please register or log in with your account to read the full publication.